Anton Birn,
CEO, DemensAI
The
diagnostic pathway for a dementia diagnosis is rapidly growing with the elder
burden. Currently, some places in Denmark experience waiting times of upwards
to 1 year from first GP visit to final diagnosis. With new drugs entering the
market, which can postpone cognitive decline, it is paramount to get an early
diagnosis.
The talk
will be presenting our study, which implemented a machine learning model to
classify between healthy control and Alzheimer's Disease patients based on 1
minute speech samples. Furthermore, it will explain where this technology could
take cognitive screenings in terms of precision, timing, scalability,
availability and cost.
DemensAI is
a pioneering startup aiming to revolutionize dementia diagnosis through
cutting-edge artificial intelligence. Founded by Anton Boldrup Birn, Laurine
Dargaud, and Abhista Partal, DemensAI's innovative AI technology utilizes
speech recognition and language analysis to assess cognitive function swiftly
and accurately.
By providing a non-invasive, digital solution, DemensAI aims to
facilitate early detection of Alzheimer's and other forms of dementia,
ultimately paving the way for timely intervention and improved patient
outcomes.
Their vision is to empower healthcare professionals with a tool that
can efficiently screen individuals for dementia, leading to earlier diagnoses
and potentially enhancing the efficacy of emerging treatments like Lecanemab
and Donanemab.
This is from the conference "Artificial Intelligence in Healthcare".
Join the discussion about the future of healthcare at our conference, where AI's power to transform patient care through swift, accurate data processing and task automation takes center stage.
